True You Weight Loss Launches Two Clinical Trials for Non-Surgical Weight Loss
True You Weight Loss, the nation’s first dedicated endobariatric weight loss center, has announced two new FDA-authorized clinical trials focused on providing innovative, non-surgical weight loss solutions without relying on GLP-1 medications. These studies expand True You’s portfolio of ten…
PureTech’s LYT-100 Slows Lung Decline in IPF in ELEVATE Phase 2b Trial
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company, today announced positive results from the Phase 2b ELEVATE IPF trial. The study evaluated deupirfenidone (LYT-100) in patients with idiopathic pulmonary fibrosis (IPF). In this randomized, double-blind, placebo-controlled trial,…
Celltrion Gets Positive CHMP Opinion for Three Biosimilars in EU
Celltrion announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions for three of its biosimilar candidates: Eydenzelt® (CT-P42, aflibercept), Stoboclo® and Osenvelt® (CT-P41, denosumab), and Avtozma® (CT-P47, tocilizumab). These recommendations…
CompleteVue™: MultiPlan’s New Pricing Analytics Solution for Providers
MultiPlan Corporation (NYSE: MPLN), a leading provider of data-driven cost management solutions, has announced the launch of CompleteVue™, an innovative software platform designed to help health systems and healthcare providers gain valuable insights into the healthcare market using publicly available…
NextGen Healthcare Selected to Support Fairfax-Falls Church Behavioral Health Expansion
NextGen Healthcare has been selected by the Fairfax-Falls Church Community Services Board (CSB) to enhance its healthcare services for residents in Fairfax County, Virginia, and neighboring cities. The CSB, dedicated to providing lifesaving support for individuals with mental health challenges,…
QuidelOrtho Appoints Two Independent Directors to Board
QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostic technologies for point-of-care settings, clinical labs, and transfusion medicine, announced the appointment of John R. Chiminski and R. Scott Huennekens to its board of directors, effective December 6, 2024.…
Cencora Launches Accelerate Pharmacy Solutions for Hospital and Health System Support
Cencora, a global healthcare company, has unveiled its new initiative, Accelerate Pharmacy Solutions, aimed at enhancing support for hospital and health system customers. This unified portfolio of services is designed to help healthcare organizations optimize their operations and improve their…
Centene Corporation Releases 2025 Guidance
Centene Corporation (NYSE: CNC), a leading healthcare enterprise focused on improving the lives of its members, has provided its financial guidance for 2025 during its investor day event. The company reaffirmed its commitment to delivering high-quality care to more than…
CVS Health Announces Expiration and Results of Tender Offer
CVS Health Corporation (NYSE: CVS) has announced the results of its previously disclosed cash tender offer (the “Any and All Tender Offer”) for its 4.100% Senior Notes due 2025 (the “Any and All Notes”). As of 5:00 p.m. New York…
BrightPath Bio and Cellistic Announce Collaboration for Phase 1 BCMA CAR-iNKT Cell Trial
BrightPath Bio (Tokyo Stock Exchange Growth 4594), a leader in iPS cell-derived Natural Killer T (NKT) cell therapy, and Cellistic, a pioneer in advanced iPS cell therapy manufacturing, have announced a new agreement focused on process development and manufacturing. The…
Merck Gets Positive EU CHMP Opinion for WELIREG®
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the conditional approval of WELIREG® (belzutifan). This oral…
Newron and EA Pharma Announce Evenamide License Agreement for Japan and Asia
Newron Pharmaceuticals S.p.A. has entered into a license agreement with EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., to develop, manufacture, and commercialize Newron’s innovative glutamate modulator, evenamide, for the treatment of schizophrenia in Japan and other Asian…